165 related articles for article (PubMed ID: 15373069)
1. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
[No Abstract] [Full Text] [Related]
2. Determining the relative efficacy of highly active antiretroviral therapy.
Louie M; Hogan C; Di Mascio M; Hurley A; Simon V; Rooney J; Ruiz N; Brun S; Sun E; Perelson AS; Ho DD; Markowitz M
J Infect Dis; 2003 Mar; 187(6):896-900. PubMed ID: 12660935
[TBL] [Abstract][Full Text] [Related]
3. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
4. New drugs in development.
Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
[TBL] [Abstract][Full Text] [Related]
5. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
Manfredi R; Calza L; Chiodo F
AIDS; 2004 Nov; 18(17):2331-3. PubMed ID: 15577549
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
[TBL] [Abstract][Full Text] [Related]
7. Treating advanced HIV infection.
Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
[No Abstract] [Full Text] [Related]
8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
9. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
HIV Clin Trials; 2008; 9(4):238-46. PubMed ID: 18753118
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
11. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
[No Abstract] [Full Text] [Related]
12. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
13. Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Wandeler G; Furrer H; Rauch A
AIDS; 2011 Nov; 25(18):2306-8. PubMed ID: 22067200
[No Abstract] [Full Text] [Related]
14. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
[No Abstract] [Full Text] [Related]
15. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
16. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ
J Infect Dis; 2008 Jul; 198(2):234-40. PubMed ID: 18540803
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
18. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Hill A; Marcelin AG; Calvez V
HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
[TBL] [Abstract][Full Text] [Related]
19. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
20. Seven-year follow-up on lopinavir/ ritonavir monotherapy.
Pierone G; Mieras J; Martin A; Urban T
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):191-2. PubMed ID: 19414830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
